Table 1.
Clinical characteristics of SLE patients
| Clinical characteristics of SLE patients | Result (%) |
|---|---|
| Age (years) | 44.7±13.81 |
| Sex ratio (M/F) | 1:9 |
| Duration (years) | 11.5±7.9 |
| SLEDAI | 6.6±7.5 |
| NPSLE | 2 (3%) |
| Visual disturbance | 1 (1%) |
| Arthritis | 8 (10%) |
| Myositis | 2 (3%) |
| Urinary casts | 15 (19%) |
| Hematuria | 9 (11%) |
| Proteinuria | 18 (23%) |
| New rash | 11 (14%) |
| Alopecia | 4 (5%) |
| Mucosal ulcers | 8 (10%) |
| Pleurisy/pericarditis | 7 (9%) |
| Low complementa | 46 (58%) |
| IgG (mg/dL) | 1,501±563.7 |
| Increased DNA bindingb | 39 (49%) |
| Fever | 10 (13%) |
| Thrombocytopenia | 7 (9%) |
| Leukopenia | 12 (15%) |
| Medication | |
| Prednisolone dosage (mg) | 10.9±10.9 |
| Mycophenolate mofetil | 12 (15%) |
| Tacrolimus | 8 (10%) |
| Cyclosporine | 3 (4%) |
| Azathioprine | 6 (8%) |
| Cyclophosphamide | 2 (3%) |
Note:
a
C3 <65 mg/dL or C4 <13 mg/dL or CH50 <30 mg/dL;
b
>2.5% binding in Farr assay or above normal range for laboratory testing.
Abbreviations: IgG, immunoglobulin G; NPSLE, neuropsychiatric SLE; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.